“The injectable drug delivery market is expected to reach $547.8 billion by 2020 from $326.1 billion in 2015, growing at a CAGR of 12.0% from 2015 to 2020. The market is categorized on the basis of type, therapeutic application, usage pattern, mode of administration, end user, and region. The therapeutic application market is further segmented into autoimmune diseases, hormonal disorders, oncology, orphan diseases, and other therapeutic applications. The oncology segment is expected to witness the highest CAGR in the forecast period.
Factors such as rising incidences of chronic diseases, growth of the biologics market, demand of self-injection devices, and technological advancements, are driving the growth of the injectable drug delivery market. In addition, emphasis on innovation of formulations and improving the delivery of pharmaceuticals is also contributing to the growth of the market. For instance, in November 2012, COMPACT (Collaboration on the Optimization of Macromolecular Pharmaceutical Access to Cellular Targets), a public-private consortium funded by the Innovative Medicines Initiative (IMI), announced the launch of a โฌ30 million ($38.5 million) project, which focuses on improving the delivery of biopharmaceuticals. The consortium would address the major bottlenecks in the development of novel innovative medicines based on biological macromolecules, such as proteins/peptides and oligonucleotides. Such investments are fueling the growth of the market.
Asia is expected to be the fastest-growing country in the injectable drug delivery market. High growth in this market can be attributed to the increased demand for injectable insulin and self-injection devices, particularly pen injectors which are used in the treatment of diabetes.
Apart from comprehensive geographic and product analysis and market sizing, the report also provides a competitive landscape that covers the growth strategies adopted by industry players over the last three years. In addition, the company profiles comprise basic views on key players in the injectable drug delivery market and product portfolios, developments, and strategies adopted by market players to maintain and increase their market shares in the near future. The above-mentioned market research data, current market size, and forecast of future trends will help key players and new entrants to make the necessary decisions regarding product offerings, geographical focus, change in strategic approach, R&D investments for innovations in products and technologies, and levels of output in order to remain successful.
Reasons to Buy the Report:
The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn will help firms to garner a greater market share. Firms purchasing the report can use one or a combination of the below-mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market shares.
The report provides insights on the following pointers:
โข Market Penetration: Comprehensive information on the product portfolios of the top players in the injectable drug delivery market. The report analyzes this market by type, therapeutic application, usage pattern, mode of administration, end user, and region
โข Product Development/Innovation: Detailed insights on upcoming technologies, R&D activities, and new product launches in the injectable drug delivery market
โข Competitive Assessment: In-depth assessment of market strategies, geographical and business segments, and product portfolios of leading players in the injectable drug delivery market
โข Market Development: Comprehensive information about lucrative markets. The report analyzes the market for various injectable drug delivery across countries
โข Market Diversification: Exhaustive information about new products and services, untapped geographies, recent developments, and investments in the injectable drug delivery market
”
“TABLE OF CONTENTS
1 INTRODUCTION 23
1.1 OBJECTIVES OF THE STUDY 23
1.2 MARKET DEFINITION 23
1.3 MARKET SCOPE 24
1.3.1 MARKETS COVERED 24
1.3.2 YEARS CONSIDERED FOR THE STUDY 28
1.4 CURRENCY 28
1.5 LIMITATIONS 28
1.6 STAKEHOLDERS 28
2 RESEARCH METHODOLOGY 29
2.1 MARKET SIZE ESTIMATION 30
2.2 MARKET BREAKDOWN AND DATA TRIANGULATION 32
2.3 KEY DATA FROM SECONDARY SOURCES 34
2.4 KEY DATA FROM PRIMARY SOURCES 34
2.5 ASSUMPTIONS FOR THE STUDY 35
3 EXECUTIVE SUMMARY 36
4 PREMIUM INSIGHTS 39
4.1 INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION 39
4.2 INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN 39
4.3 INJECTABLE DRUG DELIVERY MARKET, BY MODE OF ADMINISTRATION 40
4.4 INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION 41
4.5 GEOGRAPHICAL SNAPSHOT OF THE INJECTABLE DRUG DELIVERY MARKET 42
5 MARKET OVERVIEW 43
5.1 INTRODUCTION 44
5.2 MARKET SEGMENTATION 44
5.2.1 BY TYPE 45
5.2.2 BY THERAPEUTIC APPLICATION 45
5.2.3 BY USAGE PATTERN 46
5.2.4 BY MODE OF ADMINISTRATION 46
5.2.5 BY END USER 46
5.2.6 BY REGION 47
5.3 MARKET DYNAMICS 47
5.4 DRIVERS 49
5.4.1 RISING PREVALENCE OF CHRONIC DISEASES 49
5.4.2 INCREASE IN DEMAND FOR SELF-INJECTION DEVICES 50
5.4.3 GROWTH OF THE BIOLOGICS MARKET 50
5.4.4 TECHNOLOGICAL ADVANCEMENTS 50
5.5 RESTRAINTS 52
5.5.1 NEEDLESTICK INJURIES AND INFECTIONS 52
5.6 OPPORTUNITIES 53
5.6.1 INCREASE IN DEMAND FOR BIOSIMILARS AND GENERIC INJECTABLES 53
5.6.1.1 Biosimilars 53
5.6.1.2 Generic injectables 53
5.6.2 CONTRACEPTIVE INJECTABLES 54
5.7 CHALLENGES 55
5.7.1 PRODUCT RECALLS 55
5.7.2 REGULATORY HURDLES 56
5.7.3 STABILITY OF PRODUCTS 57
5.7.4 STERILITY OF INJECTIONS 57
5.7.5 PREFERENCE FOR OTHER MODES OF DRUG DELIVERY 58
6 INJECTABLE DRUG DELIVERY MARKET, BY TYPE 60
6.1 INTRODUCTION 61
6.2 DEVICES 62
6.2.1 CONVENTIONAL INJECTION DEVICES 63
6.2.1.1 By Material 64
6.2.1.1.1 Glass 65
6.2.1.1.2 Plastic 66
6.2.1.2 By Product 67
6.2.1.2.1 Fillable syringes 67
6.2.1.2.2 Prefilled syringes 68
6.2.1.3 By Usability 69
6.2.1.3.1 Reusable syringes 69
6.2.1.3.2 Disposable syringes 70
6.2.2 SELF-INJECTION DEVICES 70
6.2.2.1 Needle-free injectors 72
6.2.2.1.1 By product 73
6.2.2.1.1.1 Fillable needle-free injectors 73
6.2.2.1.1.2 Prefilled needle-free injectors 74
6.2.2.1.2 By technology 74
6.2.2.1.2.1 Jet-based needle-free injectors 75
6.2.2.1.2.2 Spring-based Needle-free injectors 75
6.2.2.1.2.3 Laser-powered needle-free injectors 76
6.2.2.1.2.4 Vibration-based needle-free injectors 77
6.2.2.1.3 By usability 77
6.2.2.1.3.1 Reusable needle-free injectors 78
6.2.2.1.3.2 Disposable needle-free injectors 79
6.2.2.2 Autoinjectors 79
6.2.2.2.1 By product 80
6.2.2.2.1.1 Fillable Autoinjectors 80
6.2.2.2.1.2 Prefilled Autoinjectors 81
6.2.2.2.2 By technology 82
6.2.2.2.2.1 Automated Autoinjectors 82
6.2.2.2.2.2 Manual Autoinjectors 83
6.2.2.2.3 By design 83
6.2.2.2.3.1 Standardized Autoinjectors 84
6.2.2.2.3.2 Customized Autoinjectors 85
6.2.2.2.4 By usability 85
6.2.2.2.4.1 Reusable Autoinjectors 86
6.2.2.2.4.2 Disposable Autoinjectors 87
6.2.2.3 Pen injectors 87
6.2.2.3.1 By product 88
6.2.2.3.1.1 Single-chambered Pen Injectors 89
6.2.2.3.1.2 Dual-chambered Pen Injectors 89
6.2.2.3.2 By design 90
6.2.2.3.2.1 Standard Pen Injectors 90
6.2.2.3.2.2 Customized Pen Injectors 91
6.2.2.3.3 By usability 91
6.2.2.3.3.1 Reusable Pen Injectors 92
6.2.2.3.3.2 Disposable Pen Injectors 92
6.2.2.4 Wearable injectors 93
6.2.2.5 Other Devices 94
6.3 FORMULATIONS 94
6.3.1 CONVENTIONAL DRUG DELIVERY 96
6.3.1.1 SOLUTIONS 97
6.3.1.2 RECONSTITUTED/LYOPHILIZED FORMULATIONS 97
6.3.1.3 SUSPENSIONS 98
6.3.1.4 EMULSIONS 99
6.3.2 NOVEL DRUG DELIVERY FORMULATIONS 99
6.3.2.1 COLLOIDAL DISPERSIONS 101
6.3.2.1.1 LIPOSOMES 102
6.3.2.1.2 NIOSOMES 102
6.3.2.1.3 POLYMERIC/MIXED MICELLES 103
6.3.2.1.4 NANOPARTICLES 104
6.3.2.1.4.1 NANOSUSPENSIONS 105
6.3.2.1.4.2 NANOEMULSIONS/MICROEMULSIONS 105
6.3.2.1.4.3 SOLID-LIPID NANOPARTICLES 106
6.3.2.2 MICROPARTICLES 106
6.3.2.2.1 MICROSPHERES 107
6.3.2.2.2 MICROCAPSULES 108
6.3.3 LONG-ACTING INJECTION FORMULATIONS 109
7 INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION 110
7.1 INTRODUCTION 111
7.2 AUTOIMMUNE DISEASES 113
7.2.1 RHEUMATOID ARTHRITIS 114
7.2.2 MULTIPLE SCLEROSIS 115
7.2.3 CROHNโS DISEASE 116
7.2.4 PSORIASIS 117
7.2.5 OTHER AUTOIMMUNE DISEASES 118
7.3 HORMONAL DISORDERS 119
7.3.1 DIABETES 120
7.3.2 ANEMIA 121
7.3.3 REPRODUCTIVE HEALTH DISEASE 121
7.3.4 ANTITHROMBOTIC/THROMBOLYTIC THERAPY 122
7.3.5 OSTEOPOROSIS 123
7.3.6 GROWTH HORMONE DEFICIENCY (GHD) 124
7.4 ORPHAN DISEASES 125
7.5 ONCOLOGY 126
7.6 OTHERS 127
7.6.1 PAIN MANAGEMENT 128
7.6.2 ALLERGY TREATMENT 129
7.6.3 AESTHETIC TREATMENTS 130
7.6.4 HEPATITIS C 130
7.6.5 HEMOPHILIA 131
8 INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN 133
8.1 INTRODUCTION 134
8.2 CURATIVE CARE 135
8.3 IMMUNIZATION 135
8.4 OTHER USAGE PATTERNS (BLOOD TRANSFUSION AND BLOOD PRODUCTS, AND CONTRACEPTIVES) 137
9 INJECTABLE DRUG DELIVERY MARKET, BY MODE OF ADMINISTRATION 138
9.1 INTRODUCTION 139
9.2 SKIN 140
9.3 CIRCULATORY/MUSCULOSKELETAL 140
9.4 ORGANS 141
9.5 CENTRAL NERVOUS SYSTEM 142
10 INJECTABLE DRUG DELIVERY MARKET, BY END USER 143
10.1 INTRODUCTION 144
10.2 HOSPITALS AND CLINICS 146
10.3 HOME CARE SETTINGS 146
10.4 RESEARCH LABORATORIES 147
10.5 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES 148
10.6 OTHER END USERS 149
11 INJECTABLE DRUG DELIVERY MARKET, BY REGION 150
11.1 INTRODUCTION 151
11.2 NORTH AMERICA 152
11.2.1 U.S. 157
11.2.2 CANADA 161
11.3 EUROPE 164
11.3.1 GERMANY 170
11.3.2 FRANCE 173
11.3.3 U.K. 177
11.3.4 ITALY 180
11.3.5 SPAIN 184
11.3.6 REST OF EUROPE (ROE) 187
11.4 ASIA 192
11.5 REST OF THE WORLD (ROW) 197
12 COMPETITIVE LANDSCAPE 202
12.1 OVERVIEW 202
12.2 MARKET SHARE ANALYSIS 203
12.3 COMPETITIVE SITUATIONS & TRENDS 204
12.3.1 NEW PRODUCT LAUNCHES 205
12.3.2 EXPANSIONS AND INVESTMENTS 207
12.3.3 ACQUISITIONS 208
12.3.4 COLLABORATIONS 209
13 COMPANY PROFILES 210
13.1 INTRODUCTION 210
13.2 BAXTER INTERNATIONAL, INC. 211
13.2.1 BUSINESS OVERVIEW 211
13.2.2 PRODUCT OFFERINGS 212
13.2.3 RECENT DEVELOPMENTS 212
13.2.4 MNM VIEW 213
13.3 BECTON, DICKINSON AND COMPANY 214
13.3.1 BUSINESS OVERVIEW 214
13.3.2 PRODUCT OFFERINGS 215
13.3.3 RECENT DEVELOPMENTS 215
13.3.4 MNM VIEW 216
13.4 GERRESHEIMER AG 217
13.4.1 BUSINESS OVERVIEW 217
13.4.2 PRODUCTS OFFERED 217
13.4.3 RECENT DEVELOPMENTS 218
13.4.4 MNM VIEW 218
13.5 PFIZER, INC. 219
13.5.1 BUSINESS OVERVIEW 219
13.5.2 PRODUCTS OFFERED 220
13.5.3 RECENT DEVELOPMENTS 221
13.5.4 MNM VIEW 221
13.6 SCHOTT AG 222
13.6.1 BUSINESS OVERVIEW 222
13.6.2 PRODUCT OFFERINGS 223
13.6.3 RECENT DEVELOPMENTS 223
13.6.4 MNM VIEW 223
13.7 ALKERMES PLC 224
13.7.1 BUSINESS OVERVIEW 224
13.7.2 PRODUCTS OFFERED 224
13.7.3 RECENT DEVELOPMENTS 225
13.8 ELI LILLY AND COMPANY 226
13.8.1 BUSINESS OVERVIEW 226
13.8.2 PRODUCTS OFFERED 227
13.8.3 RECENT DEVELOPMENTS 227
13.9 SANDOZ 228
13.9.1 BUSINESS OVERVIEW 228
13.9.2 PRODUCTS OFFERED 229
13.9.3 RECENT DEVELOPMENTS 230
13.10 TERUMO CORPORATION 231
13.10.1 BUSINESS OVERVIEW 231
13.10.2 PRODUCTS OFFERED 232
13.10.3 RECENT DEVELOPMENTS 232
13.11 TEVA PHARMACEUTICAL INDUSTRIES LTD. 233
13.11.1 BUSINESS OVERVIEW 233
13.11.2 PRODUCT OFFERINGS 234
13.11.3 RECENT DEVELOPMENTS 234
14 APPENDIX 235
14.1 INSIGHTS FROM INDUSTRY EXPERTS 235
14.2 DISCUSSION GUIDE 236
14.3 OTHER RECENT DEVELOPMENTS 239
14.4 AVAILABLE CUSTOMIZATIONS 240
14.5 RT: REAL-TIME MARKET INTELLIGENCE 240
14.6 RELATED REPORTS 241
“
“LIST OF TABLES
TABLE 1 EXAMPLES OF TECHNOLOGICAL ADVANCEMENTS (2013โ2015) 51
TABLE 2 RISING PREVALENCE OF CHRONIC DISEASES ACROSS THE GLOBE IS A MAJOR FACTOR DRIVING MARKET GROWTH 51
TABLE 3 NEEDLESTICK INJURIES AND INFECTIONS ARE MAJOR FACTORS LIMITING THE GROWTH OF THE MARKET 52
TABLE 4 INCREASE IN DEMAND FOR BIOSIMILARS OFFERS AN ARRAY OF OPPORTUNITIES FOR THE MARKET 55
TABLE 5 EXAMPLES OF PRODUCT RECALLS (2010โ2015) 56
TABLE 6 PRODUCT RECALLS ARE A SIGNIFICANT CHALLENGE FOR MARKET GROWTH 58
TABLE 7 INJECTABLE DRUG DELIVERY MARKET SIZE, BY TYPE, 2013โ2020 (USD MILLION) 61
TABLE 8 INJECTABLE DRUG DELIVERY MARKET SIZE, BY REGION,
2013โ2020 (USD MILLION) 61
TABLE 9 INJECTABLE DRUG DELIVERY DEVICES MARKET SIZE, BY TYPE,
2013โ2020 (USD MILLION) 62
TABLE 10 INJECTABLE DRUG DELIVERY DEVICES MARKET SIZE, BY REGION,
2013โ2020 (USD MILLION) 63
TABLE 11 CONVENTIONAL INJECTION DEVICES MARKET SIZE, BY REGION,
2013โ2020 (USD MILLION) 64
TABLE 12 CONVENTIONAL INJECTION DEVICES MARKET SIZE, BY MATERIAL,
2013โ2020 (USD MILLION) 64
TABLE 13 CONVENTIONAL GLASS INJECTION DEVICES MARKET SIZE, BY REGION,
2013โ2020 (USD MILLION) 65
TABLE 14 CONVENTIONAL PLASTIC INJECTION DEVICES MARKET SIZE, BY REGION,
2013โ2020 (USD MILLION) 66
TABLE 15 CONVENTIONAL INJECTION DEVICES MARKET SIZE, BY PRODUCT,
2013โ2020 (USD MILLION) 67
TABLE 16 CONVENTIONAL FILLABLE INJECTION DEVICES MARKET SIZE, BY REGION,
2013โ2020 (USD MILLION) 67
TABLE 17 CONVENTIONAL PREFILLED INJECTION DEVICES MARKET SIZE,
BY REGION, 2013โ2020 (USD MILLION) 68
TABLE 18 CONVENTIONAL INJECTION DEVICES MARKET SIZE, BY USABILITY,
2013โ2020 (USD MILLION) 69
TABLE 19 CONVENTIONAL REUSABLE INJECTION DEVICES MARKET SIZE, BY REGION,
2013โ2020 (USD MILLION) 69
TABLE 20 CONVENTIONAL DISPOSABLE INJECTION DEVICES MARKET SIZE, BY REGION, 2013โ2020 (USD MILLION) 70
TABLE 21 SELF-INJECTION DEVICES MARKET SIZE, BY TYPE, 2013โ2020 (USD MILLION) 71
TABLE 22 SELF-INJECTION DEVICES MARKET SIZE, BY REGION, 2013โ2020 (USD MILLION) 71
TABLE 23 NEEDLE-FREE INJECTORS MARKET SIZE, BY REGION, 2013โ2020 (USD MILLION) 72
TABLE 24 NEEDLE-FREE INJECTORS MARKET SIZE, BY PRODUCT,
2013โ2020 (USD MILLION) 73
TABLE 25 FILLABLE NEEDLE-FREE INJECTORS MARKET SIZE, BY REGION,
2013โ2020 (USD MILLION) 73
TABLE 26 PREFILLED NEEDLE-FREE INJECTORS MARKET SIZE, BY REGION,
2013โ2020 (USD MILLION) 74
TABLE 27 NEEDLE-FREE INJECTORS MARKET SIZE, BY TECHNOLOGY,
2013โ2020 (USD MILLION) 74
TABLE 28 JET-BASED NEEDLE-FREE INJECTORS MARKET SIZE, BY REGION,
2013โ2020 (USD MILLION) 75
TABLE 29 SPRING-BASED NEEDLE-FREE INJECTORS MARKET SIZE, BY REGION,
2013โ2020 (USD MILLION) 75
TABLE 30 LASER-POWERED NEEDLE-FREE INJECTORS MARKET SIZE, BY REGION,
2013โ2020 (USD MILLION) 76
TABLE 31 VIBRATION-BASED NEEDLE-FREE INJECTORS MARKET SIZE, BY REGION,
2013โ2020 (USD MILLION) 77
TABLE 32 NEEDLE-FREE INJECTORS MARKET SIZE, BY USABILITY,
2013โ2020 (USD MILLION) 77
TABLE 33 REUSABLE NEEDLE-FREE INJECTORS MARKET SIZE, BY REGION,
2013โ2020 (USD MILLION) 78
TABLE 34 DISPOSABLE NEEDLE-FREE INJECTORS MARKET SIZE, BY REGION,
2013โ2020 (USD MILLION) 79
TABLE 35 AUTOINJECTOR DEVICES MARKET SIZE, BY REGION, 2013โ2020 (USD MILLION) 79
TABLE 36 AUTOINJECTOR DEVICES MARKET SIZE, BY PRODUCT, 2013โ2020 (USD MILLION) 80
TABLE 37 FILLABLE AUTOINJECTOR DEVICES MARKET SIZE, BY REGION,
2013โ2020 (USD MILLION) 81
TABLE 38 PREFILLED AUTOINJECTOR DEVICES MARKET SIZE, BY REGION,
2013โ2020 (USD MILLION) 81
TABLE 39 AUTOINJECTOR DEVICES MARKET SIZE, BY TECHNOLOGY,
2013โ2020 (USD MILLION) 82
TABLE 40 AUTOMATED AUTOINJECTORS MARKET SIZE, BY REGION,
2013โ2020 (USD MILLION) 82
TABLE 41 MANUAL AUTOINJECTORS MARKET SIZE, BY REGION, 2013โ2020 (USD MILLION) 83
TABLE 42 AUTOINJECTORS MARKET SIZE, BY DESIGN, 2013โ2020 (USD MILLION) 83
TABLE 43 STANDARDIZED AUTOINJECTORS MARKET SIZE, BY REGION,
2013โ2020 (USD MILLION) 84
TABLE 44 CUSTOMIZED AUTOINJECTORS MARKET SIZE, BY REGION,
2013โ2020 (USD MILLION) 85
TABLE 45 AUTOINJECTORS MARKET SIZE, BY USABILITY, 2013โ2020 (USD MILLION) 85
TABLE 46 REUSABLE AUTOINJECTORS MARKET SIZE, BY REGION,
2013โ2020 (USD MILLION) 86
TABLE 47 DISPOSABLE AUTOINJECTORS MARKET SIZE, BY REGION,
2013โ2020 (USD MILLION) 87
TABLE 48 PEN INJECTORS MARKET SIZE, BY REGION, 2013โ2020 (USD MILLION) 88
TABLE 49 PEN INJECTORS MARKET SIZE, BY PRODUCT, 2013โ2020 (USD MILLION) 88
TABLE 50 SINGLE-CHAMBERED PEN INJECTORS MARKET SIZE, BY REGION,
2013โ2020 (USD MILLION) 89
TABLE 51 DUAL-CHAMBERED PEN INJECTORS MARKET SIZE, BY REGION,
2013โ2020 (USD MILLION) 89
TABLE 52 PEN INJECTORS MARKET SIZE, BY DESIGN, 2013โ2020 (USD MILLION) 90
TABLE 53 STANDARD PEN INJECTORS MARKET SIZE, BY REGION,
2013โ2020 (USD MILLION) 90
TABLE 54 CUSTOMIZED PEN INJECTORS MARKET SIZE, BY REGION,
2013โ2020 (USD MILLION) 91
TABLE 55 PEN INJECTORS MARKET SIZE, BY USABILITY, 2013โ2020 (USD MILLION) 91
TABLE 56 REUSABLE PEN INJECTORS MARKET SIZE, BY REGION, 2013โ2020 (USD MILLION) 92
TABLE 57 DISPOSABLE PEN INJECTORS MARKET SIZE, BY REGION,
2013โ2020 (USD MILLION) 92
TABLE 58 WEARABLE INJECTORS MARKET SIZE, BY REGION, 2013โ2020 (USD MILLION) 93
TABLE 59 OTHER DEVICES MARKET SIZE, BY REGION, 2013โ2020 (USD MILLION) 94
TABLE 60 INJECTABLE DRUG DELIVERY FORMULATIONS MARKET SIZE, BY TYPE,
2013โ2020 (USD MILLION) 95
TABLE 61 INJECTABLE DRUG DELIVERY FORMULATIONS MARKET SIZE, BY REGION,
2013โ2020 (USD MILLION) 95
TABLE 62 CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET SIZE, BY TYPE,
2013โ2020 (USD MILLION) 96
TABLE 63 CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET SIZE,
BY REGION, 2013โ2020 (USD MILLION) 96
TABLE 64 SOLUTIONS MARKET SIZE, BY REGION, 2013โ2020 (USD MILLION) 97
TABLE 65 RECONSTITUTED/LYOPHILIZED FORMULATIONS MARKET SIZE, BY REGION,
2013โ2020 (USD MILLION) 98
TABLE 66 SUSPENSIONS MARKET SIZE, BY REGION, 2013โ2020 (USD MILLION) 98
TABLE 67 EMULSIONS MARKET SIZE, BY REGION, 2013โ2020 (USD MILLION) 99
TABLE 68 NOVEL DRUG DELIVERY FORMULATIONS MARKET SIZE, BY TYPE,
2013โ2020 (USD MILLION) 100
TABLE 69 NOVEL DRUG DELIVERY FORMULATIONS MARKET SIZE, BY REGION,
2013โ2020 (USD MILLION) 100
TABLE 70 COLLOIDAL DISPERSION MARKET SIZE, BY TYPE, 2013โ2020 (USD MILLION) 101
TABLE 71 COLLOIDAL DISPERSION MARKET SIZE, BY REGION, 2013โ2020 (USD MILLION) 101
TABLE 72 LIPOSOMES MARKET SIZE, BY REGION, 2013โ2020 (USD MILLION) 102
TABLE 73 NIOSOMES MARKET SIZE, BY REGION, 2013โ2020 (USD MILLION) 103
TABLE 74 POLYMERIC/MIXED MICELLES MARKET SIZE, BY REGION,
2013โ2020 (USD MILLION) 103
TABLE 75 NANOPARTICLES MARKET SIZE, BY TYPE, 2013โ2020 (USD MILLION) 104
TABLE 76 NANOPARTICLES MARKET SIZE, BY REGION, 2013โ2020 (USD MILLION) 104
TABLE 77 NANOSUSPENSIONS MARKET SIZE, BY REGION, 2013โ2020 (USD MILLION) 105
TABLE 78 NANOEMULSIONS/MICROEMULSIONS MARKET SIZE, BY REGION,
2013โ2020 (USD MILLION) 105
TABLE 79 SOLID-LIPID NANOPARTICLES MARKET SIZE, BY REGION,
2013โ2020 (USD MILLION) 106
TABLE 80 MICROPARTICLES MARKET SIZE, BY TYPE, 2013โ2020 (USD MILLION) 107
TABLE 81 MICROPARTICLES MARKET SIZE, BY REGION, 2013โ2020 (USD MILLION) 107
TABLE 82 MICROSPHERES MARKET SIZE, BY REGION, 2013โ2020 (USD MILLION) 108
TABLE 83 MICROCAPSULES MARKET SIZE, BY REGION, 2013โ2020 (USD MILLION) 108
TABLE 84 LONG-ACTING INJECTION FORMULATIONS MARKET SIZE, BY REGION,
2013โ2020 (USD MILLION) 109
TABLE 85 INJECTABLE DRUG DELIVERY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2013โ2020 (USD MILLION) 112
TABLE 86 INJECTABLE DRUG DELIVERY MARKET SIZE FOR AUTOIMMUNE DISEASES,
BY INDICATION, 2013โ2020 (USD MILLION) 113
TABLE 87 INJECTABLE DRUG DELIVERY MARKET SIZE FOR AUTOIMMUNE DISEASES MARKET SIZE, BY REGION, 2013โ2020 (USD MILLION) 114
TABLE 88 INJECTABLE DRUG DELIVERY MARKET SIZE FOR RHEUMATOID ARTHRITIS,
BY REGION, 2013โ2020 (USD MILLION) 115
TABLE 89 INJECTABLE DRUG DELIVERY MARKET SIZE FOR MULTIPLE SCLEROSIS,
BY REGION, 2013โ2020 (USD MILLION) 116
TABLE 90 INJECTABLE DRUG DELIVERY MARKET SIZE FOR CROHNโS DISEASE, BY REGION, 2013โ2020 (USD MILLION) 117
TABLE 91 INJECTABLE DRUG DELIVERY MARKET SIZE FOR PSORIASIS, BY REGION,
2013โ2020 (USD MILLION) 118
TABLE 92 INJECTABLE DRUG DELIVERY MARKET SIZE FOR OTHER AUTOIMMUNE DISEASES, BY REGION, 2013โ2020 (USD MILLION) 118
TABLE 93 INJECTABLE DRUG DELIVERY MARKET SIZE FOR HORMONAL DISORDERS,
BY INDICATION, 2013โ2020 (USD MILLION) 119
TABLE 94 INJECTABLE DRUG DELIVERY MARKET SIZE FOR HORMONAL DISORDERS,
BY REGION, 2013โ2020 (USD MILLION) 119
TABLE 95 INJECTABLE DRUG DELIVERY MARKET SIZE FOR DIABETES, BY REGION,
2013โ2020 (USD MILLION) 120
TABLE 96 INJECTABLE DRUG DELIVERY MARKET SIZE FOR ANEMIA, BY REGION,
2013โ2020 (USD MILLION) 121
TABLE 97 INJECTABLE DRUG DELIVERY MARKET SIZE FOR REPRODUCTIVE HEALTH DISEASE, BY REGION, 2013โ2020 (USD MILLION) 122
TABLE 98 INJECTABLE DRUG DELIVERY MARKET SIZE FOR ANTITHROMBOTIC/THROMBOLYTIC THERAPY, BY REGION,
2013โ2020 (USD MILLION) 123
TABLE 99 INJECTABLE DRUG DELIVERY MARKET SIZE FOR OSTEOPOROSIS, BY REGION, 2013-2020 (USD MILLION) 124
TABLE 100 INJECTABLE DRUG DELIVERY MARKET SIZE FOR GROWTH HORMONE DEFICIENCY (GHD), BY REGION, 2013-2020 (USD MILLION) 125
TABLE 101 INJECTABLE DRUG DELIVERY MARKET SIZE FOR ORPHAN DISEASES, BY REGION, 2013-2020 (USD MILLION) 126
TABLE 102 INJECTABLE DRUG DELIVERY MARKET SIZE FOR ONCOLOGY, BY REGION,
2013-2020 (USD MILLION) 127
TABLE 103 INJECTABLE DRUG DELIVERY MARKET SIZE FOR OTHER THERAPEUTIC APPLICATIONS, BY INDICATION, 2013-2020 (USD MILLION) 127
TABLE 104 INJECTABLE DRUG DELIVERY MARKET SIZE FOR OTHER THERAPEUTIC APPLICATIONS, BY REGION, 2013-2020 (USD MILLION) 128
TABLE 105 INJECTABLE DRUG DELIVERY MARKET SIZE FOR PAIN MANAGEMENT,
BY REGION, 2013-2020 (USD MILLION) 128
TABLE 106 INJECTABLE DRUG DELIVERY MARKET SIZE FOR ALLERGY TREATMENT,
BY REGION, 2013-2020 (USD MILLION) 129
TABLE 107 INJECTABLE DRUG DELIVERY MARKET SIZE FOR AESTHETIC TREATMENTS,
BY REGION, 2013-2020 (USD MILLION) 130
TABLE 108 INJECTABLE DRUG DELIVERY MARKET SIZE FOR HEPATITIS C, BY REGION,
2013-2020 (USD MILLION) 131
TABLE 109 INJECTABLE DRUG DELIVERY MARKET SIZE FOR HEMOPHILIA, BY REGION,
2013-2020 (USD MILLION) 132
TABLE 110 INJECTABLE DRUG DELIVERY MARKET SIZE, BY USAGE PATTERN,
2013โ2020 (USD MILLION) 134
TABLE 111 CURATIVE CARE MARKET SIZE, BY REGION, 2013-2020 (USD MILLION) 135
TABLE 112 IMMUNIZATION MARKET SIZE, BY REGION, 2013-2020 (USD MILLION) 136
TABLE 113 OTHER USAGE PATTERNS MARKET SIZE, BY REGION, 2013โ2020 (USD MILLION) 137
TABLE 114 INJECTABLE DRUG DELIVERY MARKET SIZE, BY MODE OF ADMINISTRATION, 2013โ2020 (USD MILLION) 139
TABLE 115 SKIN ADMINISTRATION MARKET SIZE, BY REGION, 2013โ2020 (USD MILLION) 140
TABLE 116 CIRCULATORY/MUSCULOSKELETAL ADMINISTRATION MARKET SIZE, BY REGION, 2013โ2020 (USD MILLION) 141
TABLE 117 ORGAN ADMINISTRATION MARKET SIZE, BY REGION, 2013โ2020 (USD MILLION) 142
TABLE 118 CENTRAL NERVOUS SYSTEM ADMINISTRATION MARKET SIZE, BY REGION,
2013โ2020 (USD MILLION) 142
TABLE 119 INJECTABLE DRUG DELIVERY MARKET SIZE, BY END USER, 2013-2020 (USD MILLION) 145
TABLE 120 INJECTABLE DRUG DELIVERY MARKET SIZE, BY REGION,
2013-2020 (USD MILLION) 145
TABLE 121 HOSPITALS AND CLINICS MARKET SIZE, BY REGION, 2013-2020 (USD MILLION) 146
TABLE 122 HOME CARE SETTINGS MARKET SIZE, BY REGION, 2013-2020 (USD MILLION) 147
TABLE 123 RESEARCH LABORATORIES MARKET SIZE, BY REGION, 2013-2020 (USD MILLION) 147
TABLE 124 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES MARKET SIZE, BY REGION, 2013-2020 (USD MILLION) 148
TABLE 125 OTHER END USERS MARKET SIZE, BY REGION, 2013-2020 (USD MILLION) 149
TABLE 126 INJECTABLE DRUG DELIVERY MARKET SIZE, BY REGION,
2013-2020 (USD MILLION) 151
TABLE 127 NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION) 154
TABLE 128 NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET SIZE, BY TYPE,
2013โ2020 (USD MILLION) 154
TABLE 129 NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET SIZE, BY DEVICE,
2013โ2020 (USD MILLION) 154
TABLE 130 NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET SIZE, BY FORMULATION, 2013-2020 (USD MILLION) 155
TABLE 131 NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2013โ2020 (USD MILLION) 155
TABLE 132 NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET SIZE, BY USAGE PATTERN, 2013โ2020 (USD MILLION) 156
TABLE 133 NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET SIZE,
BY MODE OF ADMINISTRATION, 2013โ2020 (USD MILLION) 156
TABLE 134 NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET SIZE, BY END USER, 2013โ2020 (USD MILLION) 157
TABLE 135 U.S.: INJECTABLE DRUG DELIVERY MARKET SIZE, BY TYPE,
2013โ2020 (USD MILLION) 158
TABLE 136 U.S.: INJECTABLE DRUG DELIVERY MARKET SIZE, BY DEVICE,
2013โ2020 (USD MILLION) 158
TABLE 137 U.S.: INJECTABLE DRUG DELIVERY MARKET SIZE, BY FORMULATION,
2013-2020 (USD MILLION) 158
TABLE 138 U.S.: INJECTABLE DRUG DELIVERY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2013โ2020 (USD MILLION) 159
TABLE 139 U.S.: INJECTABLE DRUG DELIVERY MARKET SIZE, BY USAGE PATTERN,
2013โ2020 (USD MILLION) 159
TABLE 140 U.S.: INJECTABLE DRUG DELIVERY MARKET SIZE, BY MODE OF ADMINISTRATION, 2013โ2020 (USD MILLION) 160
TABLE 141 U.S.: INJECTABLE DRUG DELIVERY MARKET SIZE, BY END USER,
2013โ2020 (USD MILLION) 160
TABLE 142 CANADA: INJECTABLE DRUG DELIVERY MARKET SIZE, BY TYPE,
2013โ2020 (USD MILLION) 161
TABLE 143 CANADA: INJECTABLE DRUG DELIVERY MARKET SIZE, BY DEVICE,
2013โ2020 (USD MILLION) 161
TABLE 144 CANADA: INJECTABLE DRUG DELIVERY MARKET SIZE, BY FORMULATION,
2013-2020 (USD MILLION) 162
TABLE 145 CANADA: INJECTABLE DRUG DELIVERY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2013โ2020 (USD MILLION) 162
TABLE 146 CANADA: INJECTABLE DRUG DELIVERY MARKET SIZE, BY USAGE PATTERN,
2013โ2020 (USD MILLION) 163
TABLE 147 CANADA: INJECTABLE DRUG DELIVERY MARKET SIZE, BY MODE OF ADMINISTRATION, 2013โ2020 (USD MILLION) 163
TABLE 148 CANADA: INJECTABLE DRUG DELIVERY MARKET SIZE, BY END USER,
2013โ2020 (USD MILLION) 164
TABLE 149 EUROPE: INJECTABLE DRUG DELIVERY MARKET SIZE, BY COUNTRY,
2013-2020 (USD MILLION) 166
TABLE 150 EUROPE: INJECTABLE DRUG DELIVERY MARKET SIZE, BY TYPE,
2013โ2020 (USD MILLION) 166
TABLE 151 EUROPE: INJECTABLE DRUG DELIVERY MARKET SIZE, BY DEVICE,
2013โ2020 (USD MILLION) 167
TABLE 152 EUROPE: INJECTABLE DRUG DELIVERY MARKET SIZE, BY FORMULATION,
2013-2020 (USD MILLION) 167
TABLE 153 EUROPE: INJECTABLE DRUG DELIVERY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2013โ2020 (USD MILLION) 168
TABLE 154 EUROPE: INJECTABLE DRUG DELIVERY MARKET SIZE, BY USAGE PATTERN,
2013โ2020 (USD MILLION) 168
TABLE 155 EUROPE: INJECTABLE DRUG DELIVERY MARKET SIZE, BY MODE OF ADMINISTRATION, 2013โ2020 (USD MILLION) 169
TABLE 156 EUROPE: INJECTABLE DRUG DELIVERY MARKET SIZE, BY END USER,
2013โ2020 (USD MILLION) 169
TABLE 157 GERMANY: INJECTABLE DRUG DELIVERY MARKET SIZE, BY TYPE,
2013-2020 (USD MILLION) 170
TABLE 158 GERMANY: INJECTABLE DRUG DELIVERY MARKET SIZE, BY DEVICE,
2013-2020 (USD MILLION) 170
TABLE 159 GERMANY: INJECTABLE DRUG DELIVERY MARKET SIZE, BY FORMULATION,
2013โ2020 (USD MILLION) 171
TABLE 160 GERMANY: INJECTABLE DRUG DELIVERY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2013โ2020 (USD MILLION) 171
TABLE 161 GERMANY: INJECTABLE DRUG DELIVERY MARKET SIZE, BY USAGE PATTERN, 2013โ2020 (USD MILLION) 172
TABLE 162 GERMANY: INJECTABLE DRUG DELIVERY MARKET SIZE, BY MODE OF ADMINISTRATION, 2013โ2020 (USD MILLION) 172
TABLE 163 GERMANY: INJECTABLE DRUG DELIVERY MARKET SIZE, BY END USER,
2013โ2020 (USD MILLION) 173
TABLE 164 FRANCE :INJECTABLE DRUG DELIVERY MARKET SIZE, BY TYPE,
2013โ2020 (USD MILLION) 173
TABLE 165 FRANCE: INJECTABLE DRUG DELIVERY MARKET SIZE, BY DEVICE,
2013โ2020 (USD MILLION) 174
TABLE 166 FRANCE: INJECTABLE DRUG DELIVERY MARKET SIZE, BY FORMULATION,
2013-2020 (USD MILLION) 174
TABLE 167 FRANCE: INJECTABLE DRUG DELIVERY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2013โ2020 (USD MILLION) 175
TABLE 168 FRANCE: INJECTABLE DRUG DELIVERY MARKET SIZE, BY USAGE PATTERN,
2013โ2020 (USD MILLION) 175
TABLE 169 FRANCE: INJECTABLE DRUG DELIVERY MARKET SIZE, BY MODE OF ADMINISTRATION, 2013โ2020 (USD MILLION) 176
TABLE 170 FRANCE: INJECTABLE DRUG DELIVERY MARKET SIZE, BY END USER,
2013โ2020 (USD MILLION) 176
TABLE 171 U.K.: INJECTABLE DRUG DELIVERY MARKET SIZE, BY TYPE,
2013-2020 (USD MILLION) 177
TABLE 172 U.K.: INJECTABLE DRUG DELIVERY MARKET SIZE, BY DEVICE,
2013-2020 (USD MILLION) 177
TABLE 173 U.K.: INJECTABLE DRUG DELIVERY MARKET SIZE, BY FORMULATION,
2013-2020 (USD MILLION) 178
TABLE 174 U.K.: INJECTABLE DRUG DELIVERY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2013-2020 (USD MILLION) 178
TABLE 175 U.K.: INJECTABLE DRUG DELIVERY MARKET SIZE, BY USAGE PATTERN,
2013โ2020 (USD MILLION) 179
TABLE 176 U.K.: INJECTABLE DRUG DELIVERY MARKET SIZE, BY MODE OF ADMINISTRATION, 2013โ2020 (USD MILLION) 179
TABLE 177 U.K.: INJECTABLE DRUG DELIVERY MARKET SIZE, BY END USER,
2013โ2020 (USD MILLION) 180
TABLE 178 ITALY: INJECTABLE DRUG DELIVERY MARKET SIZE, BY TYPE,
2013โ2020 (USD MILLION) 180
TABLE 179 ITALY: INJECTABLE DRUG DELIVERY MARKET SIZE, BY DEVICE,
2013โ2020 (USD MILLION) 181
TABLE 180 ITALY: INJECTABLE DRUG DELIVERY MARKET SIZE, BY FORMULATION,
2013โ2020 (USD MILLION) 181
TABLE 181 ITALY: INJECTABLE DRUG DELIVERY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2013โ2020 (USD MILLION) 182
TABLE 182 ITALY: INJECTABLE DRUG DELIVERY MARKET SIZE, BY USAGE PATTERN,
2013โ2020 (USD MILLION) 182
TABLE 183 ITALY: INJECTABLE DRUG DELIVERY MARKET SIZE, BY MODE OF ADMINISTRATION, 2013โ2020 (USD MILLION) 183
TABLE 184 ITALY: INJECTABLE DRUG DELIVERY MARKET SIZE, BY END USER,
2013โ2020 (USD MILLION) 183
TABLE 185 SPAIN: INJECTABLE DRUG DELIVERY MARKET SIZE, BY TYPE,
2013โ2020 (USD MILLION) 184
TABLE 186 SPAIN: INJECTABLE DRUG DELIVERY MARKET SIZE, BY DEVICE,
2013โ2020 (USD MILLION) 184
TABLE 187 SPAIN: INJECTABLE DRUG DELIVERY MARKET SIZE , BY FORMULATION,
2013-2020 (USD MILLION) 185
TABLE 188 SPAIN: INJECTABLE DRUG DELIVERY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2013โ2020 (USD MILLION) 185
TABLE 189 SPAIN: INJECTABLE DRUG DELIVERY MARKET SIZE, BY USAGE PATTERN,
2013โ2020 (USD MILLION) 186
TABLE 190 SPAIN: INJECTABLE DRUG DELIVERY MARKET SIZE, BY MODE OF ADMINISTRATION, 2013โ2020 (USD MILLION) 186
TABLE 191 SPAIN: INJECTABLE DRUG DELIVERY MARKET SIZE, BY END USER,
2013โ2020 (USD MILLION) 187
TABLE 192 ROE: INJECTABLE DRUG DELIVERY MARKET SIZE, BY TYPE,
2013โ2020 (USD MILLION) 188
TABLE 193 ROE: INJECTABLE DRUG DELIVERY MARKET SIZE, BY DEVICE,
2013โ2020 (USD MILLION) 189
TABLE 194 ROE: INJECTABLE DRUG DELIVERY MARKET SIZE, BY FORMULATION,
2013-2020 (USD MILLION) 189
TABLE 195 ROE: INJECTABLE DRUG DELIVERY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2013โ2020 (USD MILLION) 190
TABLE 196 ROE: INJECTABLE DRUG DELIVERY MARKET SIZE, BY USAGE PATTERN,
2013โ2020 (USD MILLION) 190
TABLE 197 ROE: INJECTABLE DRUG DELIVERY MARKET SIZE, BY MODE OF ADMINISTRATION, 2013โ2020 (USD MILLION) 191
TABLE 198 ROE: INJECTABLE DRUG DELIVERY MARKET SIZE, BY END USER,
2013โ2020 (USD MILLION) 191
TABLE 199 ASIA: INJECTABLE DRUG DELIVERY MARKET SIZE, BY TYPE,
2013โ2020 (USD MILLION) 194
TABLE 200 ASIA: INJECTABLE DRUG DELIVERY MARKET SIZE, BY DEVICE,
2013โ2020 (USD MILLION) 194
TABLE 201 ASIA: INJECTABLE DRUG DELIVERY MARKET SIZE, BY FORMULATION,
2013-2020 (USD MILLION) 194
TABLE 202 ASIA: INJECTABLE DRUG DELIVERY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2013โ2020 (USD MILLION) 195
TABLE 203 ASIA: INJECTABLE DRUG DELIVERY MARKET SIZE, BY USAGE PATTERN,
2013โ2020 (USD MILLION) 195
TABLE 204 ASIA: INJECTABLE DRUG DELIVERY MARKET SIZE, BY MODE OF ADMINISTRATION, 2013โ2020 (USD MILLION) 196
TABLE 205 ASIA: INJECTABLE DRUG DELIVERY MARKET SIZE, BY END USER,
2013โ2020 (USD MILLION) 196
TABLE 206 ROW: INJECTABLE DRUG DELIVERY MARKET SIZE, BY TYPE,
2013โ2020 (USD MILLION) 199
TABLE 207 ROW: INJECTABLE DRUG DELIVERY MARKET SIZE, BY DEVICE,
2013โ2020 (USD MILLION) 199
TABLE 208 ROW: INJECTABLE DRUG DELIVERY MARKET SIZE, BY FORMULATION,
2013-2020 (USD MILLION) 199
TABLE 209 ROW: INJECTABLE DRUG DELIVERY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2013โ2020 (USD MILLION) 200
TABLE 210 ROW: INJECTABLE DRUG DELIVERY MARKET SIZE, BY USAGE PATTERN,
2013โ2020 (USD MILLION) 200
TABLE 211 ROW: INJECTABLE DRUG DELIVERY MARKET SIZE, BY MODE OF ADMINISTRATION, 2013โ2020 (USD MILLION) 201
TABLE 212 ROW: INJECTABLE DRUG DELIVERY MARKET SIZE, BY END USER,
2013โ2020 (USD MILLION) 201
TABLE 213 NEW PRODUCT LAUNCHES, 2014-2015 205
TABLE 214 MAJOR APPROVALS, 2014-2015 206
TABLE 215 EXPANSIONS AND INVESTMENTS, 2013-2015 207
TABLE 216 ACQUISITIONS, 2014-2015 208
TABLE 217 COLLABORATIONS, 2014-2015 209
“
“LIST OF FIGURES
FIGURE 1 RESEARCH DESIGN 29
FIGURE 2 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH 31
FIGURE 3 MARKET SIZE ESTIMATION: TOP-DOWN APPROACH 31
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION,
AND REGION 32
FIGURE 5 DATA TRIANGULATION METHODOLOGY 33
FIGURE 6 INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION, 2015 VS. 2020 36
FIGURE 7 INJECTABLE DRUG DELIVERY MARKET, BY DEVICE, 2015 VS. 2020 37
FIGURE 8 HOSPITALS AND CLINICS TO FORM THE LARGEST END-USER SEGMENT 37
FIGURE 9 INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION,
2015 VS. 2020 38
FIGURE 10 INJECTABLE DRUG DELIVERY FORMULATIONS MARKET TO GROW AT THE HIGHEST CAGR FROM 2015 TO 2020 39
FIGURE 11 THE CURATIVE CARE SEGMENT TO WITNESS THE HIGHEST GROWTH RATE IN THE FORECAST PERIOD 39
FIGURE 12 SKIN SEGMENT TO ACCOUNT FOR THE LARGEST SHARE IN 2015 40
FIGURE 13 HORMONAL DISORDERS SEGMENT TO ACCOUNT FOR THE LARGEST SHARE
IN 2015 41
FIGURE 14 ASIA TO WITNESS HIGHEST GROWTH RATE DURING THE FORECAST PERIOD 42
FIGURE 15 INJECTABLE DRUG DELIVERY MARKET SEGMENTATION, BY TYPE 45
FIGURE 16 INJECTABLE DRUG DELIVERY MARKET SEGMENTATION, BY THERAPEUTIC APPLICATION 45
FIGURE 17 INJECTABLE DRUG DELIVERY MARKET SEGMENTATION, BY USAGE PATTERN 46
FIGURE 18 INJECTABLE DRUG DELIVERY MARKET SEGMENTATION, BY MODE OF ADMINISTRATION 46
FIGURE 19 INJECTABLE DRUG DELIVERY MARKET SEGMENTATION, BY END USER 46
FIGURE 20 INJECTABLE DRUG DELIVERY MARKET SEGMENTATION, BY REGION 47
FIGURE 21 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE INJECTABLE DRUG DELIVERY MARKET 48
FIGURE 22 INJECTABLE DRUG DELIVERY THERAPEUTIC APPLICATIONS MARKET, BY REGION, 2013โ2020 (USD MILLION) 111
FIGURE 23 THERAPEUTIC APPLICATIONS: ONCOLOGY TO SHOW HIGHEST GROWTH DURING THE FORECAST PERIOD 112
FIGURE 24 INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN: CURATIVE CARE SEGMENT TO HOLD LARGEST SHARE 134
FIGURE 25 INJECTABLE DRUG DELIVERY MARKET, BY MODE OF ADMINISTRATION: SKIN SEGMENT TO SHOW HIGHEST GROWTH 139
FIGURE 26 INJECTABLE DRUG DELIVERY MARKET SEGMENTATION, BY END USER 144
FIGURE 27 INJECTABLE DRUG DELIVERY MARKET, BY END USER: HOSPITALS AND CLINICS TO HOLD LARGEST MARKET SHARE IN 2015 144
FIGURE 28 NORTH AMERICA TO HOLD THE LARGEST SHARE OF THE GLOBAL INJECTABLE DRUG DELIVERY MARKET (2015) 153
FIGURE 29 EUROPEAN INJECTABLE DRUG DELIVERY MARKET SNAPSHOT (2015) 165
FIGURE 30 ROE: SELF-INJECTION DEVICES MARKET SNAPSHOT 188
FIGURE 31 ASIA TO BE THE FASTEST-GROWING REGIONAL SEGMENT OF THE GLOBAL INJECTABLE DRUG DELIVERY MARKET (2015) 193
FIGURE 32 RISING PREVALENCE OF CHRONIC DISEASES TO DRIVE THE GROWTH OF THE INJECTABLE DRUG DELIVERY MARKET IN THE ROW (2015) 198
FIGURE 33 NEW PRODUCT LAUNCHES, KEY GROWTH STRATEGY BETWEEN 2012 & 2015 202
FIGURE 34 GLOBAL INJECTABLE DRUG DELIVERY MARKET SHARE, BY KEY PLAYER (2014) 203
FIGURE 35 MARKET EVOLUTION FRAMEWORK: PARTNERSHIPS, AGREEMENTS, AND COLLABORATIONS & EXPANSIONS ARE FUELING MARKET GROWTH 204
FIGURE 36 BATTLE FOR MARKET SHARE: NEW PRODUCT LAUNCHES WAS THE KEY STRATEGY ADOPTED BY LEADING PLAYERS, 2014 205
FIGURE 37 PRODUCT BENCHMARKING FOR TOP 5 PLAYERS 210
FIGURE 38 BAXTER INTERNATIONAL, INC.: COMPANY SNAPSHOT 211
FIGURE 39 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT 214
FIGURE 40 GERRESHEIMER AG: COMPANY SNAPSHOT 217
FIGURE 41 PFIZER, INC.: COMPANY SNAPSHOT 219
FIGURE 42 SCHOTT AG: COMPANY SNAPSHOT 222
FIGURE 43 ALKERMES PLC: COMPANY SNAPSHOT 224
FIGURE 44 ELI LILLY AND COMPANY: COMPANY SNAPSHOT 226
FIGURE 45 SANDOZ: COMPANY SNAPSHOT 228
FIGURE 46 TERUMO CORPORATION: COMPANY SNAPSHOT 231
FIGURE 47 TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT 233
“
- Previous: Modular UPS Market by Solution Type (10-100 kVA, 101-250 kVA, 251-500 kVA, Above 501 kVA), Service Type (System Integration and Professional), Vertical Type, and Region (NA, Europe, APAC, LA and MEA) – Global Forecast to 2020
- Next: Global Modular Uninterruptible Power Supply (UPS) Market is Expected to Reach USD 1,425.2 Million in 2015
